Anlotinib Plus Penpulimab as Second-line Treatment for Patients With Small Cell Lung Cancer After Failure of Platinum-based Chemotherapy

NCT05001971 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

65

Enrollment

OTHER

Sponsor class

Conditions

Small Cell Lung Cancer

Interventions

DRUG: Anlotinib Plus Penpulimab

Sponsor

Hunan Cancer Hospital

Collaborators

[object Object]
[object Object]